NO20004527L - Modulatorer for proteintyrosinfosfataser (PTPaser) - Google Patents
Modulatorer for proteintyrosinfosfataser (PTPaser)Info
- Publication number
- NO20004527L NO20004527L NO20004527A NO20004527A NO20004527L NO 20004527 L NO20004527 L NO 20004527L NO 20004527 A NO20004527 A NO 20004527A NO 20004527 A NO20004527 A NO 20004527A NO 20004527 L NO20004527 L NO 20004527L
- Authority
- NO
- Norway
- Prior art keywords
- diseases
- compounds
- ptpases
- protein tyrosine
- shp
- Prior art date
Links
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title abstract 4
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 101100466198 Mus musculus Ptpra gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrodes Of Semiconductors (AREA)
- Enzymes And Modification Thereof (AREA)
- Bipolar Transistors (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Control Of El Displays (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK34498 | 1998-03-12 | ||
| DK48098 | 1998-04-03 | ||
| DKPA199800938 | 1998-07-15 | ||
| DKPA199801385 | 1998-10-28 | ||
| DKPA199801612 | 1998-12-07 | ||
| PCT/DK1999/000121 WO1999046267A1 (en) | 1998-03-12 | 1999-03-11 | Modulators of protein tyrosine phosphatases (ptpases) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004527D0 NO20004527D0 (no) | 2000-09-11 |
| NO20004527L true NO20004527L (no) | 2000-11-07 |
Family
ID=27512769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004527A NO20004527L (no) | 1998-03-12 | 2000-09-11 | Modulatorer for proteintyrosinfosfataser (PTPaser) |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1080095B1 (de) |
| JP (1) | JP2002506072A (de) |
| KR (1) | KR20010041814A (de) |
| CN (1) | CN1300291A (de) |
| AT (1) | ATE308546T1 (de) |
| AU (1) | AU2713599A (de) |
| BR (1) | BR9908726A (de) |
| CA (1) | CA2323493A1 (de) |
| DE (1) | DE69928100D1 (de) |
| HU (1) | HUP0104984A3 (de) |
| IL (1) | IL138319A0 (de) |
| NO (1) | NO20004527L (de) |
| PL (1) | PL342816A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049632A1 (en) | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| WO2003103647A1 (ja) * | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ａｐ−１及びｎｆａｔ活性化阻害剤 |
| WO2003103648A1 (ja) * | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| CA2488367A1 (en) | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
| KR20110028554A (ko) | 2002-06-06 | 2011-03-18 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | Ｏ-치환 히드록시아릴 유도체 |
| JP4881297B2 (ja) * | 2004-05-28 | 2012-02-22 | フォーエスシー アクチエンゲゼルシャフト | 新規のテトラヒドロピリドチオフェン |
| ES2308504T3 (es) * | 2004-06-04 | 2008-12-01 | 4Sc Ag | Tetrahidropiridotiofenos para su utilizacion en el tratamiento del cancer. |
| AU2005251485A1 (en) * | 2004-06-11 | 2005-12-22 | 4Sc Ag | Tetrahydropyridothiophenes for treating hyperproliferative disorders |
| RS56873B1 (sr) * | 2004-06-24 | 2018-04-30 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| AU2006212224A1 (en) * | 2005-02-09 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| AU2006212179A1 (en) * | 2005-02-11 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| JP4908511B2 (ja) * | 2005-09-15 | 2012-04-04 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アミノ−チエノ［３，２−ｃ］ピリジン−７−カルボン酸誘導体 |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| DK3252057T3 (da) | 2009-12-04 | 2024-06-17 | Sunovion Pharmaceuticals Inc | Multicykliske forbindelser og fremgangsmåder til anvendelse deraf |
| CN102382076B (zh) * | 2010-09-03 | 2016-08-17 | 中国医学科学院药物研究所 | 芳酮和芳酰胺类化合物及其制法和药物用途 |
| CN102838625B (zh) * | 2011-06-22 | 2015-04-15 | 中国科学院上海药物研究所 | 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
| US9682967B2 (en) * | 2013-01-28 | 2017-06-20 | H. Lundbeck A/S | N-substituted-5-substituted phthalamic acids as sortilin inhibitors |
| CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
| CN106748999A (zh) * | 2015-03-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
| CN106866523A (zh) * | 2015-03-12 | 2017-06-20 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104829629B (zh) * | 2015-03-26 | 2017-03-15 | 天津药物研究院有限公司 | 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途 |
| SG11201900687VA (en) | 2016-07-29 | 2019-02-27 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| IL264446B2 (en) | 2016-07-29 | 2024-09-01 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| KR102605854B1 (ko) | 2017-02-16 | 2023-11-23 | 선오비온 파마슈티컬스 인코포레이티드 | 조현병의 치료방법 |
| EP3661929B1 (de) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochromanverbindungen und verwendungen davon |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| US11136304B2 (en) | 2019-03-14 | 2021-10-05 | Sunovion Pharmaceuticals Inc. | Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| US12410191B2 (en) * | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| CN115461056B (zh) * | 2020-04-14 | 2024-04-16 | 普渡研究基金会 | 淋巴特异性酪氨酸磷酸酶(lyp)抑制剂 |
| US11738002B2 (en) | 2020-04-14 | 2023-08-29 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
-
1999
- 1999-03-11 AT AT99907332T patent/ATE308546T1/de not_active IP Right Cessation
- 1999-03-11 BR BR9908726-0A patent/BR9908726A/pt not_active IP Right Cessation
- 1999-03-11 AU AU27135/99A patent/AU2713599A/en not_active Abandoned
- 1999-03-11 KR KR1020007010093A patent/KR20010041814A/ko not_active Withdrawn
- 1999-03-11 DE DE69928100T patent/DE69928100D1/de not_active Expired - Lifetime
- 1999-03-11 CA CA002323493A patent/CA2323493A1/en not_active Abandoned
- 1999-03-11 CN CN99806016A patent/CN1300291A/zh active Pending
- 1999-03-11 HU HU0104984A patent/HUP0104984A3/hu unknown
- 1999-03-11 EP EP99907332A patent/EP1080095B1/de not_active Expired - Lifetime
- 1999-03-11 PL PL99342816A patent/PL342816A1/xx not_active Application Discontinuation
- 1999-03-11 JP JP2000535645A patent/JP2002506072A/ja not_active Withdrawn
- 1999-03-11 IL IL13831999A patent/IL138319A0/xx unknown
-
2000
- 2000-09-11 NO NO20004527A patent/NO20004527L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2713599A (en) | 1999-09-27 |
| EP1080095B1 (de) | 2005-11-02 |
| JP2002506072A (ja) | 2002-02-26 |
| NO20004527D0 (no) | 2000-09-11 |
| BR9908726A (pt) | 2000-11-21 |
| HUP0104984A2 (hu) | 2002-04-29 |
| PL342816A1 (en) | 2001-07-02 |
| KR20010041814A (ko) | 2001-05-25 |
| ATE308546T1 (de) | 2005-11-15 |
| CA2323493A1 (en) | 1999-09-16 |
| EP1080095A1 (de) | 2001-03-07 |
| CN1300291A (zh) | 2001-06-20 |
| IL138319A0 (en) | 2001-10-31 |
| HUP0104984A3 (en) | 2003-07-28 |
| DE69928100D1 (de) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20004527L (no) | Modulatorer for proteintyrosinfosfataser (PTPaser) | |
| Vallés et al. | Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes | |
| Cheng et al. | Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis | |
| Park et al. | Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation | |
| Su et al. | Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB 2 receptors | |
| Majka et al. | Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization | |
| Miwa et al. | Lipopolysaccharide enhances synthesis of brain‐derived neurotrophic factor in cultured rat microglia | |
| Tang et al. | Wnt-1 promotes neuronal differentiation and inhibits gliogenesis in P19 cells | |
| AU2002329540A1 (en) | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof | |
| Huh et al. | Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway | |
| DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
| ATE348828T1 (de) | Beta-carbolin-derivate als ptp-inhibitoren | |
| Calkins et al. | Differential effects of recombinant interleukin-1α and β on Leydig cell function | |
| BRPI0407446A (pt) | Anticorpos para c-met para o tratamento de cânceres | |
| BR9909660A (pt) | Inibidores de caspases | |
| Chowdhury et al. | Dynamic compression counteracts IL-1β induced inducible nitric oxide synthase and cyclo-oxygenase-2 expression in chondrocyte/agarose constructs | |
| Yang et al. | Amygdalin isolated from Semen Persicae (Tao Ren) extracts induces the expression of follistatin in HepG2 and C2C12 cell lines | |
| Kim et al. | 3-Deoxysappanchalcone promotes proliferation of human hair follicle dermal papilla cells and hair growth in C57BL/6 mice by modulating WNT/β-Catenin and STAT signaling | |
| DE69732712D1 (de) | INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS | |
| Wang et al. | Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation | |
| Zhang et al. | YY1 promotes IL-6 expression in LPS-stimulated BV2 microglial cells by interacting with p65 to promote transcriptional activation of IL-6 | |
| BRPI0414793A (pt) | uso do fator anti-secretor | |
| Li et al. | Expression of fibroblast growth factors in rat dorsal root ganglion neurons and regulation after peripheral nerve injury | |
| Handschin et al. | Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro | |
| EA200401586A1 (ru) | Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста |